OptimizeRx Co. (NASDAQ:OPRX) Given Average Recommendation of “Moderate Buy” by Brokerages

OptimizeRx Co. (NASDAQ:OPRX) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $16.07.

Several research firms recently issued reports on OPRX. Royal Bank of Canada reiterated an “outperform” rating and issued a $17.00 price objective on shares of OptimizeRx in a report on Monday, April 1st. B. Riley initiated coverage on shares of OptimizeRx in a research note on Thursday. They set a “buy” rating and a $18.50 target price on the stock. Stifel Nicolaus reissued a “buy” rating and issued a $13.00 price target on shares of OptimizeRx in a research report on Wednesday, May 15th. Finally, JMP Securities restated a “market outperform” rating and set a $16.00 price target on shares of OptimizeRx in a report on Friday, June 21st.

Hedge Funds Weigh In On OptimizeRx

A number of institutional investors and hedge funds have recently modified their holdings of OPRX. Bank of New York Mellon Corp increased its holdings in shares of OptimizeRx by 9.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 111,719 shares of the company’s stock valued at $1,117,000 after acquiring an additional 10,041 shares during the last quarter. AWM Investment Company Inc. increased its stake in OptimizeRx by 4.0% in the first quarter. AWM Investment Company Inc. now owns 853,042 shares of the company’s stock valued at $10,364,000 after purchasing an additional 33,000 shares during the last quarter. First Light Asset Management LLC grew its position in shares of OptimizeRx by 0.6% in the 1st quarter. First Light Asset Management LLC now owns 1,737,584 shares of the company’s stock valued at $21,112,000 after buying an additional 10,286 shares during the last quarter. Vanguard Group Inc. raised its stake in OptimizeRx by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company’s stock worth $12,482,000 after acquiring an additional 6,291 shares in the last quarter. Finally, Blair William & Co. IL lifted its position in OptimizeRx by 5.6% in the first quarter. Blair William & Co. IL now owns 782,573 shares of the company’s stock valued at $9,508,000 after acquiring an additional 41,469 shares during the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Price Performance

OPRX stock opened at $10.70 on Friday. The stock has a market cap of $195.49 million, a price-to-earnings ratio of -10.49 and a beta of 1.26. OptimizeRx has a 52-week low of $6.92 and a 52-week high of $16.65. The business has a fifty day moving average of $10.99 and a two-hundred day moving average of $12.37. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.26.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.16). OptimizeRx had a negative net margin of 23.10% and a negative return on equity of 6.96%. The company had revenue of $19.69 million for the quarter, compared to analyst estimates of $18.66 million. During the same quarter in the prior year, the business earned ($0.34) earnings per share. As a group, research analysts anticipate that OptimizeRx will post -0.42 earnings per share for the current year.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.